Atlas Trials

A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL

Clinical trial NCT06573645 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06573645
Sponsor
Xia Yi
Status
NOT_YET_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Lymphoma, Large B-Cell, Diffuse
Start date
2024-08-23
Primary completion
2027-01-12
Enrollment
428

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.